FFA
IGC icon

Fairfield Financial Advisors’s IGC Pharma IGC Stock Holding History

Fairfield Financial Advisors’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$474 – 312
2022
Q1 		$474 Buy
+500
New +$486 ﹤0.01% 299

Other funds holding IGC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Fairfield Financial Advisors's IGC Position: Q2 2022 in Review

Fairfield Financial Advisors sold out of IGC Pharma (IGC) in Q2 2022, closing a stake of 500 shares — an estimated $474 sold.

Fairfield Financial Advisors first reported a position in IGC in Q1 2022 and held it in 1 quarter. The position peaked at $474 in Q1 2022. 29 funds tracked by Wall St. Rank hold IGC as of Q2 2022.

  • Fairfield Financial Advisors reported no remaining IGC Pharma position as of Q2 2022 after selling out during the quarter.
  • Fairfield Financial Advisors sold 500 IGC Pharma shares in Q2 2022, an estimated $474.
  • Fairfield Financial Advisors first reported a position in IGC Pharma in Q1 2022 and held it in 1 quarter.
  • Fairfield Financial Advisors's IGC Pharma position peaked at $474 in Q1 2022.
  • 29 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2022.

Based on Fairfield Financial Advisors's 13F filing for Q2 2022, filed 7 Oct 2024.